Risk of rhabdomyolysis from 5 ‐α reductase inhibitors

Conclusion5‐α reductase inhibitors do not appear to be associated with the development of rhabdomyolysis; however, they may be associated with an increased risk of myopathy and myositis.

Source: Pharmacoepidemiology and Drug Safety - January 1, 2018 Category: Drugs & Pharmacology Authors: Blayne Welk, Eric McArthur, Michael Ordon, Jade Dirk, Stephanie Dixon, Amit X. Garg Tags: BRIEF REPORT Source Type: research